Stebbings Richard, Wang Lili, Sutherland Janet, Kammel Martin, Gaigalas Adolfas K, John Manuela, Roemer Bodo, Kuhne Maren, Schneider Rudolf J, Braun Michael, Engel Andrea, Dikshit Dinesh K, Abbasi Fatima, Marti Gerald E, Sassi Maria Paola, Revel Laura, Kim Sook-Kyung, Baradez Marc-Olivier, Lekishvili Tamara, Marshall Damian, Whitby Liam, Jing Wang, Ost Volker, Vonsky Maxim, Neukammer Jörg
Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC), South Mimms, Potters Bar, Hertfordshire, EN6 3QG, United Kingdom.
Cytometry A. 2015 Mar;87(3):244-53. doi: 10.1002/cyto.a.22614. Epub 2015 Feb 5.
A surface-labeled lyophilized lymphocyte (sLL) preparation has been developed using human peripheral blood mononuclear cells prelabeled with a fluorescein isothiocyanate conjugated anti-CD4 monoclonal antibody. The sLL preparation is intended to be used as a reference material for CD4+ cell counting including the development of higher order reference measurement procedures and has been evaluated in the pilot study CCQM-P102. This study was conducted across 16 laboratories from eight countries to assess the ability of participants to quantify the CD4+ cell count of this reference material and to document cross-laboratory variability plus associated measurement uncertainties. Twelve different flow cytometer platforms were evaluated using a standard protocol that included calibration beads used to obtain quantitative measurements of CD4+ T cell counts. There was good overall cross-platform and counting method agreement with a grand mean of the laboratory calculated means of (301.7 ± 4.9) μL(-1) CD4+ cells. Excluding outliers, greater than 90% of participant data agreed within ±15%. A major contribution to variation of sLL CD4+ cell counts was tube to tube variation of the calibration beads, amounting to an uncertainty of 3.6%. Variation due to preparative steps equated to an uncertainty of 2.6%. There was no reduction in variability when data files were centrally reanalyzed. Remaining variation was attributed to instrument specific differences. CD4+ cell counts obtained in CCQM-P102 are in excellent agreement and show the robustness of both the measurements and the data analysis and hence the suitability of sLL as a reference material for interlaboratory comparisons and external quality assessment.
已开发出一种表面标记的冻干淋巴细胞(sLL)制剂,该制剂使用异硫氰酸荧光素偶联的抗CD4单克隆抗体预标记的人外周血单核细胞。sLL制剂旨在用作CD4+细胞计数的参考物质,包括高阶参考测量程序的开发,并已在CCQM-P102试点研究中进行了评估。这项研究在来自八个国家的16个实验室中进行,以评估参与者对该参考物质的CD4+细胞计数进行定量的能力,并记录跨实验室的变异性以及相关的测量不确定度。使用标准方案评估了12种不同的流式细胞仪平台,该方案包括用于获得CD4+ T细胞计数定量测量的校准微球。总体而言,跨平台和计数方法具有良好的一致性,实验室计算平均值的总平均值为(301.7±4.9)μL-1 CD4+细胞。排除异常值后,超过90%的参与者数据在±15%范围内一致。校准微球管间差异是sLL CD4+细胞计数变异的主要贡献因素,其不确定度为3.6%。制备步骤引起的变异相当于2.6%的不确定度。对数据文件进行集中重新分析时,变异性没有降低。剩余的变异归因于仪器的特定差异。CCQM-P102中获得的CD4+细胞计数具有极好的一致性,表明测量和数据分析的稳健性,因此sLL适合作为实验室间比较和外部质量评估的参考物质。